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The Epstein-Barr virus (EBV) BMRF1 gene encodes an early lytic protein that functions not only as the viral
DNA polymerase processivity factor but also as a transcriptional activator. BMRF1 has been previously shown
to activate transcription of an EBV early promoter, BHLF1, though a GC-rich motif which binds to SP1 and
ZBP-89, although the exact mechanism for this effect is not known (D. J. Law, S. A. Tarle, and J. L. Merchant,
Mamm. Genome 9:165–167, 1998). Here we demonstrate that BMRF1 activates transcription of the cellular
gastrin gene in telomerase-immortalized keratinocytes. Furthermore, BMRF1 activated a reporter gene con-
struct driven by the gastrin promoter in a variety of cell types, and this effect was mediated by two SP1/ZBP-89
binding sites in the gastrin promoter. ZBP-89 has been previously shown to negatively regulate the gastrin
promoter. However, ZBP-89 can function as either a negative or positive regulator of transcription, depending
upon the promoter and perhaps other, as-yet-unidentified factors. BMRF1 increased the binding of ZBP-89 to
the gastrin promoter, and a ZBP-89-GAL4 fusion protein was converted into a positive transcriptional
regulator by cotransfection with BMRF1. BMRF1 also enhanced the transcriptional activity of an SP1-GAL4
fusion protein. These results suggest that BMRF1 activates target promoters through its effect on both the SP1
and ZBP-89 transcription factors. Furthermore, as the EBV genome is present in up to 10% of gastric cancers,
and the different forms of gastrin are growth factors for gastrointestinal epithelium, our results suggest a
mechanism by which lytic EBV infection could promote the growth of gastric cells.
Epstein-Barr virus (EBV) is a human herpesvirus that in-
fects most individuals and causes the clinical syndrome infec-
tious mononucleosis. The EBV genome is commonly found in
certain malignancies, including African Burkitt lymphoma, B-
cell lymphomas in immunocompromised patients, and naso-
pharyngeal carcinoma (22, 40). The EBV genome is also found
in a subset (approximately 10%) of gastric carcinomas (50).
The exact role of EBV infection in the development of gastric
cancer, if any, remains unclear.
Like all herpesviruses, EBV can infect cells in either the
latent or the lytic form. While EBV infection in B cells usually
results in one of the latent forms of infection, infection of oral
epithelial cells (as exemplified by the lateral tongue lesion oral
hairy leukoplakia) (39) is normally completely lytic (53). Nev-
ertheless, in the epithelial tumor nasopharyngeal carcinoma,
most cells contain the type II form of latent viral infection, and
only a small percentage of tumor cells are lytically infected
(33). In EBV-positive gastric carcinoma cells, the majority of
tumor cells are also found to contain a latent form of viral
infection (50). However, the lytic form of EBV infection is also
found in a small number of EBV-positive gastric carcinoma
cells (18). Whether normal gastric epithelial cells are infected
by EBV in healthy individuals remains unknown.
During the lytic form of EBV infection, viral replication is
mediated by the virally encoded DNA polymerase, using an
origin of replication referred to as oriLyt (11, 15). EBV DNA
polymerase activity requires both the catalytic component of
the enzyme (encoded by the EBV BALF5 gene) as well as the
polymerase processivity activity (encoded by the BMRF1 gene)
(23, 52). Interestingly, the BMRF1 gene product has also been
shown to transcriptionally activate an early EBV promoter,
BHLF1 (63–65).
BHLF1 is one of two divergent early promoters contained
within the lytic origin of replication, oriLyt (10, 15). BMRF1
activation of the BHLF1 promoter is mediated by a GC-rich
motif that binds to both SP1 and ZBP-89 (3, 14, 64). Further-
more, the BMRF1-responsive region of the BHLF1 promoter
is also required in cis for oriLyt replication (3, 42). In addition,
BMRF1 has been reported to interact directly with both the
ZBP-89 and SP1 proteins (3). A model suggesting that the
interaction between BMRF1 and ZBP-89/SP1 bound to oriLyt
may be essential for the formation of the initial replication
complex has been proposed (3). However, what the mechanism
for the BMRF1 transcriptional effect is and whether the tran-
scriptional effect of BMRF1 is essential for oriLyt replication
are not yet known.
In this report, we demonstrate that BMRF1 transcriptionally
activates the cellular gastrin promoter. Microarray analysis of
telomerase-immortalized keratinocytes (TIK cells) infected
with a BMRF1 adenovirus vector or a control adenovirus vec-
tor indicated that BMRF1 greatly enhances gastrin gene ex-
pression. This result was subsequently confirmed by Northern
blot analysis. BMRF1 also activated the gastrin promoter
linked to the luciferase gene in HeLa, AGS, DG75, and Raji
cells. The BMRF1 effect was mediated through two GC-rich
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motifs in the gastrin promoter which are bound by both SP1
and ZBP-89. ZBP-89 has been previously shown to be a neg-
ative regulator of the gastrin promoter, while SP1 is a positive
regulator (29, 34). BMRF1 enhanced ZBP-89 binding to the
gastrin promoter without affecting SP1 binding. However,
BMRF1 significantly activated the transcriptional function of
GAL4 fusion proteins linked to either the ZBP-89 or SP1
protein. These results suggest that BMRF1 activates target
promoters through its effects on both the SP1 and ZBP-89
cellular transcription factors.
MATERIALS AND METHODS
Cell culture. Human TIK cells were originally derived from human neonatal
foreskin as previously described (24) and were maintained in keratinocyte serum-
free medium (Gibco BRL) with epidermal growth factor and bovine pituitary
extract added. The AGS cell line, purchased from The American Type Culture
Collection, is an EBV-negative gastric carcinoma line maintained in Ham’s F-12
medium with 10% fetal bovine serum. HeLa cells are a cervical carcinoma
epithelial line maintained in Dulbecco’s modified Eagle medium with 5% fetal
bovine serum. DG75 is an EBV-negative B-cell line. Raji is an EBV-positive
Burkitt line. NPC-KT is an EBV-positive epithelial line derived from a fusion of
a human adenoidal epithelial cell line and a primary EBV-positive nasopharyn-
geal carcinoma (51). All media contained penicillin (100 U/ml) and streptomycin
(100 U/ml), and cells were maintained at 37°C in a humidified atmosphere
containing 10% CO2.
Plasmid vectors. The BMRF1 expression vector (SG5-BMRF1) has been
previously described (65) and contains the 1,341-bp BclI-BglII fragment of the
EBV BamHI M fragment subcloned into the BamHI and BglII sites of the SG5
vector (Stratagene) under the control of the simian virus 40 early promoter (a gift
from David Dorsky). In-frame deletions of the BMRF1 protein removing various
residues of the carboxy-terminal transactivator domain were also constructed as
previously described (63). A gastrin reporter construct containing the wild-type
human gastrin promoter linked to the luciferase gene, 240GASLuc, as well as a
series of site-directed mutants in the 240GASLuc construct, were constructed as
previously described (43). Additionally, a site-directed mutation of the potential
AP2 site was created in the 240GASLuc reporter construct using the unique site
elimination method (7). The mutagenic primer carrying the desired mutation in
the AP2 element contained 15 complimentary nucleotides on either side of a
4-bp substitution (underlined). The oligo-nucleotide used was 242-5 CTGG
AGAGCTGCCGCTTTTCCGCTCCAGCCCCTC. The SP1-GAL4 and ZBP-89
GAL4 fusion proteins were constructed as previously described (3) and were a
gift from W. Hammerschmidt. The SG424 control vector (expressing the GAL4
DNA binding domain alone) and the GAL4-E1b-CAT plasmid (containing five
copies of the GAL4 DNA binding motif upstream of a minimal adenovirus E1B
promoter driving the chloramphenicol acetyltransferase [CAT] gene) were con-
structed as previously described (31) and were gifts from M. Green. Vectors
expressing the rat ZBP-89 cDNA (with or without a Flag tag) under the control
of the cytomegalovirus immediate early promoter in the pcDNA3 vector (In-
vitrogen) were constructed as previously described (1, 34).
Reporter gene assays. Epithelial cells were transfected by using FuGENE 6
(Roche) or Lipofectamine 2000 (Invitrogen) with plasmids that had been puri-
fied by using the Qiagen Maxiprep kit. Lymphoid cells were transfected by
electroporation with 1,500 V from a Zapper electroporation unit (Medical Elec-
tronics Shop, University of Wisconsin). CAT assays were performed as previ-
ously described (13) by using extracts harvested 48 h posttransfection. The
percent acetylation of chloramphenicol was quantitated by thin-layer chroma-
tography followed by PhosphorImager (Molecular Dynamics) scanning. Lucif-
erase assays were performed 48 h after transfection by using extracts prepared by
freeze-thawing the cell pellet in 0.25 M Tris, pH 7.5. Luciferase activity was
determined with an Auto Lumat LB953 luminometer (EG&G Berthold) in an
assay buffer containing 12.5 mM glycylglycine, 2 mM EGTA, 7.5 mM MgSO4, 7.5
mM K2HPO4, 0.5 mM dithiothreitol (DTT), 1 mM ATP, 100 M luciferin, and
50 mM Tris.
Adenoviral vectors and infections. An E1/E3-deficient adenovirus vector ex-
pressing the EBV BMRF1 protein under the control of the human cytomegalo-
virus immediate-early promoter (AdBMRF1) was made by using the recombi-
nant Cre-lox-mediated recombination system as previously described (56). The
control adenovirus vector (AdLacZ) is identical to AdBMRF1 except that it
contains the bacterial -galactosidase gene in place of the BMRF1 gene. All
adenovirus preparations were confirmed to be free of detectable wild-type virus.
Adenovirus infections of telomerase-immortalized human keratinocytes were
performed with a multiplicity of infection of 20.
Affymetrix gene chip analysis. Telomerase-immortalized human keratinocytes
were plated at 2  107 cells per 150-mm dish and then either mock infected or
infected with adenovirus expressing LacZ or BMRF1. The cells were harvested
48 h later, and total RNA was obtained with an RNeasy kit (Qiagen). From each
condition, cDNA was then synthesized using a T7-dT24 primer (cDNA kit from
Life Technologies). Biotinylated cRNA was then generated from the cDNA
reaction by using a BioArray high-yield RNA transcription kit. The cRNA was
then fragmented in fragmentation buffer (5 fragmentation buffer: 200 mM Tris
acetate [OAc], pH 8.1; 500 mM KOAc; 150 mM MgOAc) at 94°C for 35 min
before chip hybridization. Fragmented cRNA (15 g) was then added to a
hybridization cocktail (0.05 g of fragmented cRNA per l; 50 pM control
oligonucleotide B2; BioB, BioC, BioD, and cre hybridization controls; 0.1 mg of
herring sperm DNA per ml; 0.5 mg of acetylated bovine serum albumin per ml;
100 mM morpholineethanesulfonic acid; 1 M [Na]; 20 mM EDTA; 0.01%
Tween 20) and a GeneChip HuGeneFL array, which provides gene expression
data for approximately 5,000 full-length human sequences. Arrays were hybrid-
ized for 16 h in a GeneChip Fluidics Station 400 and were washed and scanned
with a Hewlett Packard gene array scanner. During the washing, the cRNA probe
was labeled with R-phycoerythrin streptavidin. Affymetrix GeneChip microarray
suite 4.0 software was used for washing, scanning, and basic analysis. Sample
quality was assessed by examination of 3-to-5 intensity ratios of certain genes.
Northern blotting. Total RNA was prepared with an RNeasy kit (Qiagen)
according to the manufacturer’s instructions. Total RNA (10 g) was subjected
to denaturing agarose gel electrophoresis, and fractionated RNA was transferred
to a Nytran SuPerCharge membrane by using the Turboblotter system (Schlei-
cher and Schuell) according to the manufacturer’s specifications. Following
transfer, RNA was cross-linked to the membrane via UV irradiation (1,200 J). A
DNA probe directed against the gastrin cDNA was amplified by reverse tran-
scription (RT)-PCR, gel purified with a Qiagen gel extraction kit, and 32P-
radiolabeled with a Prime-A-Gene kit (Promega). A labeled GAPDH probe
(Ambion) was used as a control. Unincorporated radioactivity was removed with
Sephadex G-50 columns (Amersham). Prehybridization and hybridization (2 
FIG. 1. BMRF1 activates gastrin transcription in TIK cells. (a) TIK
cells were mock infected or infected with adenovirus vectors expressing
LacZ or BMRF1. Cellular RNA was harvested 2 days later and ana-
lyzed by Northern blot analysis for expression of gastrin or GAPDH.
AGS gastrin carcinoma cells served as a positive control for gastrin
transcription. (b) TIK cells were transfected with SG5 vector DNA or
the SG5-BMRF1 expression plasmid. RNA was harvested 2 days later,
and gastrin RNA expression was examined by RT-PCR with gastrin-
specific primers. Untransfected AGS cells served as a positive control
for gastrin expression.
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106 cpm of probe) were performed in Quikhyb solution (Stratagene) according
to the manufacturer’s instructions.
Immunoblotting. Cell extracts were lysed in NP-40 lysis buffer supplemented
with protease and phosphatase inhibitors. Equivalent amounts of proteins were
separated on sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis
gels and blotted on a nitrocellulose membrane. The membranes were then
blocked in blocking buffer (1 phosphate-buffered saline [PBS], 0.1% Tween 20,
5% milk) at room temperature for 60 min and then incubated at room temper-
ature for 60 min with either a primary antibody directed against BMRF1 (1:
5,000; E-ED-71 clone, a gift from Janos Luka, Eastern Virginia Medical School)
or 0.5 g of mouse M2 anti-Flag (Sigma) per ml in blocking buffer. The mem-
branes were washed in wash buffer (1 PBS, 0.1% Tween 20) and incubated with
horseradish peroxidase-conjugated secondary antibody (1:10,000; Promega) at
room temperature for 60 min. The membranes were washed in wash buffer, and
proteins were detected by enhanced chemiluminescence (detection reagents for
enhanced chemiluminescence Western blotting were from Amersham Bio-
sciences).
EMSAs. For electrophoretic mobility shift assays (EMSAs), DG75 cells were
transfected with SG5 vector, BMRF1 vector, Flag-tagged ZBP-89 alone, or the
combination of BMRF1 and Flag-tagged ZBP-89. Whole-cell extracts were pre-
pared 48 h after transfection. Briefly, cells were washed with PBS followed by
resuspension in lysis buffer (50 mM HEPES, pH 7.9; 250 mM NaCl; 0.1% NP-40; 5
mM EDTA; 5 mM DTT; 1 Complete protease inhibitors [Roche]; 15% glycerol).
Cells were lysed by three freeze-thaw cycles. Cellular debris was removed by cen-
trifugation at 10,000  g for 15 min. Supernatants were removed and used as
whole-cell extracts. Oligonucleotides containing the two potential ZBP-89/SP1 bind-
ing sites in the gastrin promoter that contained gastrin promoter sequences from
47 to 74 (5GATCAGGGTAGGGGCGGGGTGGGGGGACAGTT) and from
120 to 153 (5GATCGACACTAAATGAAAGGGCGGGGCAGGGTGAT
GGG) were constructed and labeled with [-32P]dCTP by using the Klenow frag-
ment of DNA polymerase I (New England Biolabs). Oligonucleotides containing the
ZBP-89/SP1 binding site in oriLyt that spanned genomic EBV sequences from 53517
to 53570 (5GATCTGGCCTGTGCCTTGTCCCGTGGACAATGTCCCTCCAGC
GTGGTGGCTGCC) were constructed. Binding reaction mixtures contained 5 to
10 g of nuclear extract and 20,000 cpm of radiolabeled oligonucleotide in 10 mM
Tris (pH 8.0), 100 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 1 mM
ZnSO4, 10% glycerol, and 1 g of dI-dC. Binding reactions were performed at room
temperature for 30 min. For antibody supershift experiments, 0.2 g of antibody was
incubated with whole-cell extract for 30 min prior to the addition of radiolabeled
probe. The antibodies used were mouse MOPC 21 immunoglobulin G (Sigma),
mouse M2 anti-Flag (Sigma), mouse anti-human Sp1 (Santa Cruz), and mouse
anti-human Sp3 (Santa Cruz). Binding reaction mixtures were electrophoresed in
5% nondenaturing polyacrylamide gels containing 0.5 Tris-borate-EDTA buffer
and 5% glycerol. Gels were dried, and protein-DNA complexes were visualized by
autoradiography.
RT-PCR. Total RNA was isolated from NPC-KT cells treated with or without
iododeoxyuridine (75 g/ml) for 48 h (to induce expression of lytic EBV genes,
including the BMRF1 gene), from AGS cells, and from TIK cells transfected
with the SG5 or SG5-BMRF1 expression plasmids. Gastrin mRNA expression
was quantified by RT-PCR as previously described, using 35 cycles (12). The
gastrin primers (5ATGCAGCGACTATGTGTGTGTATGT for the forward
primer and 5TTCTCATCCTCAGCACTGCGGCGGC for the reverse primer)
produced a 383-bp product corresponding to exons 2 and 3. Primers for 2-
microglobin were 5TTCTGGCCTGGAGGGCATCC (forward) and 5ATCTTC
AAACCTCCATGATG (reverse).
RESULTS
BMRF1 activates gastrin expression. To examine the effect
of BMRF1 on cellular gene expression, we performed microar-
ray analysis using an Affymetrix chip containing 5,000 cellular
genes and RNA isolated from TIK cells which were mock
infected, infected with an adenovirus vector expressing LacZ
(AdLacZ), or infected with an adenovirus vector expressing
BMRF1 (AdBMRF1). The microarray analysis indicated that
cells infected with AdBMRF1 expressed the cellular gastrin
gene at a 34-fold-higher level than the mock-infected cells or
the AdLacZ-infected cells (data not shown). Since gastrin ex-
pression is normally limited to specialized neuroendocrine-like
cells in the stomach (the G cells) (21), the finding that BMRF1
FIG. 2. BMRF1 activates the gastrin promoter. A construct containing the gastrin promoter driving the luciferase gene was cotransfected with
either SG5 vector DNA or the SG5-BMRF1 expression vector into four different cell types (AGS gastric carcinoma cells, DG75 B cells, HeLa
cervical carcinoma cells, and Raji Burkitt lymphoma cells). The amount of luciferase activity produced by each condition is indicated. Data are
means  standard errors.
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activates gastrin expression in a nongastric epithelial cell was
unexpected.
To confirm that BMRF1 activates gastrin expression, we
performed Northern blot analysis of RNA from TIK cells that
were mock infected or infected with the AdLacZ or Ad-
BMRF1 vector. RNA from AGS gastric carcinoma cells served
as a positive control for gastrin expression. Compared to the
mock-infected and AdLacZ-infected cells, TIK cells infected
with the AdBMRF1 vector had a dramatically increased level
of gastrin expression (Fig. 1a). In addition, RT-PCR analysis
confirmed that TIK cells transfected with a BMRF1 expression
plasmid had considerably more gastrin expression than cells
transfected with the SG5 vector control (Fig. 1b). However,
BMRF1 did not activate gastrin expression in AGS cells (data
not shown), possibly because gastrin is already highly ex-
pressed in these cells. These results indicate that BMRF1 ac-
tivates gastrin gene expression in TIK cells and that this effect
is not dependent upon the adenovirus vector.
BMRF1 activates the gastrin promoter. To determine if
BMRF1 enhances the activity of the gastrin promoter, a re-
porter gene construct containing the human gastrin promoter
linked to the luciferase gene was transfected into HeLa cells
(an EBV-negative cervical carcinoma line), AGS cells (an
EBV-negative gastric carcinoma line), DG75 cells (an EBV-
negative B-cell line) or Raji cells (an EBV-positive Burkitt
lymphoma line) in the presence or absence of cotransfected
BMRF1 (Fig. 2). In HeLa cells, where the gastrin promoter by
itself is essentially silent, BMRF1 markedly activated the gas-
trin-luciferase construct. In contrast, BMRF1 had little, if any,
effect on the promoterless luciferase vector (data not shown).
BMRF1 also enhanced the activity of the gastrin promoter in
AGS cells, a cell type where the gastrin promoter is constitu-
tively active, although the effect was less than that in HeLa
cells. In addition, BMRF1 increased gastrin promoter activity
in both DG75 cells and Raji cells. Thus, BMRF1 enhances the
activity of the gastrin promoter in both epithelial and B-cell
lines and in the presence or absence of the EBV genome.
Efficient BMRF1 activation of the gastrin promoter requires
residues 379 to 383 in the carboxy-terminal domain. The car-
boxy-terminal domain of BMRF1 (residues 300 to 404) is re-
quired for its transcriptional function (63). It was previously
shown that residues 379 to 383 in the BMRF1 carboxy-terminal
domain are required for efficient activation of the oriLyt
BHLF1 promoter but are not required for nuclear transloca-
tion of the protein (63). In contrast, BMRF1 residues 316 to
378 are not required for activation of the BHLF1 promoter
(63). To determine if residues 379 to 383 or 316 to 378 are
required for BMRF1 activation of the gastrin promoter, we
compared the ability of the wild-type versus mutant proteins to
activate the gastrin promoter in HeLa and AGS cells (Fig. 3a).
The wild-type protein was clearly superior to the mutant pro-
tein missing residues 379 to 383 in its ability to activate the
gastrin promoter in both HeLa and AGS cells, even though the
proteins are expressed at similar levels (63). In contrast, dele-
tion of BMRF1 sequences from 316 to 378 enhanced its ability
to activate the gastrin promoter. The wild-type and mutant
BMRF1 proteins were all expressed at similar levels (Fig. 3b).
Thus, residues 379 to 383 in BMRF1 are required for efficient
activation of the gastrin promoter as well as the BHLF1 pro-
moter, while residues 316 to 378 are dispensable or even in-
hibitory.
Two SP1/ZBP-89 binding sites mediate BMRF1 activation
of the gastrin promoter. To further define the region(s) in the
gastrin promoter required for activation by BMRF1, we exam-
ined the ability of BMRF1 to activate the wild-type gastrin
FIG. 3. BMRF1 residues 379 to 383 are required for activation of
the gastrin promoter. (a) The gastrin promoter-luciferase construct
was cotransfected into AGS cells or HeLa cells with SG5 vector DNA,
wild-type BMRF1, BMRF1 with an in frame deletion from residues
316 to 378, or BMRF1 with an in-frame deletion from residues 379 to
383. The increase in luciferase activity (in comparison to the SG5
vector) produced by the wild-type versus mutant BMRF1 proteins is
shown. Data are means  standard errors. (b) Immunoblot of trans-
fected wild-type BMRF1, BMRF1 with an in-frame deletion from
residues 316 to 378, or BMRF1 with an in-frame deletion from resi-
dues 379 to 383.
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promoter compared to gastrin promoter constructs containing
the site-directed mutations shown in Fig. 4a. A mutant pro-
moter construct altering promoter sequences between 220
and 223 (abolishing a potential AP-2 site) did not affect
BMRF1 transactivation in AGS cells (Fig. 4b). Two mutations
(altering sequences from 135 to 138 or from 61 to 64)
that each abolished one of the two known SP1 sites in the
gastrin promoter also had no effect. However, a construct
containing both the 135 to 138 mutation and the 61 to
64 mutation was significantly impaired in its ability to be
activated by BMRF1 in AGS cells. These results suggest that
the BMRF1 responsiveness of the gastrin promoter is con-
ferred independently through two SP1 binding sites. Presum-
ably, mutation of either SP1 site alone does not eliminate
BMRF1 responsiveness in the gastrin promoter, as the other
SP1 site can still respond to BMRF1. However, as the 61 to
64 mutation also abolishes an overlapping ZBP-89 binding
site, BMRF1 could potentially affect ZBP-89, rather than SP1,
transcriptional function.
The gastrin promoter has two ZBP-89 binding sites. Al-
though the gastrin promoter sequences affected by the 61 to
64 mutation have been previously shown to bind to both
ZBP-89 and SP1, ZBP-89 binding to the promoter sequences
between 120 and 148 has not been previously examined. To
determine if ZBP-89 also binds to this region of the gastrin
promoter, EMSA assays were performed using reticulocyte
lysate alone or ZBP-89 protein translated in vitro with reticu-
locyte lysate. 32P-labeled oligonucleotide probes containing the
gastrin promoter sequences from 74 to 47 (AGGGTAGG
GGCGGGGTGGGGGGACAGTT) or from 153 to 120
(GACACTAAATGAAAGGGCGGGGCAGGGTGATG
GG), or a probe encompassing the previously defined strong
ZBP-89 binding site in EBV oriLyt (3), were examined for
ZBP-89 binding activity (Fig. 5). In vitro-translated ZBP-89
FIG. 4. BMRF1 activation of the gastrin promoter is mediated through two SP1 binding sites. (a) Site-directed mutations altering sequences
in the gastrin promoter containing a potential AP2 site, an upstream SP1 site, a downstream SP1/ZBP-89 site, or the combination of both SP1 sites
were constructed as shown. (b) The wild-type and mutant gastrin promoter constructs were cotransfected into AGS cells with SG5 vector DNA
or the SG5-BMRF1 expression vector, and the amount of luciferase activity was determined. The activation in luciferase activity induced by
BMRF1 (relative to the SG5 vector) for the wild-type versus mutant gastrin promoter constructs is shown. Data are means  standard errors.
VOL. 79, 2005 BMRF1 ACTIVATES GASTRIN 749
bound to both of the gastrin promoter probes, although
ZBP-89 clearly bound much more efficiently to the EBV oriLyt
binding site than to either gastrin promoter site. Thus, both of
the BMRF1-responsive regions of the gastrin promoter con-
tain relatively weak ZBP-89 binding sites.
BMRF1 enhances binding of ZBP-89 to the gastrin pro-
moter in vivo. To determine if BMRF1 affects the binding of
ZBP-89 to the gastrin promoter in vivo, we transfected DG75
cells with either a vector control or a Flag-tagged ZBP-89
expression vector in the presence or absence of cotransfected
BMRF1 and prepared extracts from the transfected cells for
EMSAs. Transfected BMRF1 did not significantly affect the
binding of endogenous SP1 to the gastrin probe containing
promoter sequences from 47 to 74 (Fig. 6a). However,
binding of the transfected Flag-tagged ZBP-89 protein, which
was difficult to detect in the absence of BMRF1, was clearly
enhanced in the presence of BMRF1. Similar results were
obtained with the gastrin promoter probe containing se-
quences between 153 and 120 (data not shown). The levels
of transfected ZBP-89 protein were similar in the presence and
absence of cotransfected BMRF1 (Fig. 6b). These results sug-
gest that BMRF1 enhances ZBP-89 binding to the gastrin
promoter.
BMRF1 enhances the transcriptional activity of both SP1
and ZBP-89. The finding that BMRF1 enhances ZBP-89 bind-
ing to the gastrin promoter was unexpected, given that ZBP-89
by itself has been previously shown to be a negative regulator
of the gastrin promoter (29, 34), yet BMRF1 enhances gastrin
promoter activity. In contrast to ZBP-89, SP1 is a positive
regulator of the gastrin promoter (29, 34). As SP1 and ZBP-89
sites are often overlapping (as is the case in the gastrin pro-
moter), it is difficult to construct deletions that specifically
inhibit ZBP-89 versus SP1 binding. To separate the effects of
BMRF1 on SP1 and ZBP-89 transcriptional function, we ex-
amined whether BMRF1 can activate either SP1 or ZBP-89
fusion proteins linked in frame to the GAL4 DNA binding
domain. SP1-GAL4 and ZBP-89-GAL4 fusion proteins were
cotransfected with a reporter plasmid containing five copies of
the GAL4 DNA binding site upstream of a minimal promoter
element (adenovirus E1b) and the CAT gene, in the presence
or absence of cotransfected BMRF1. As seen in Fig. 7,
BMRF1 activated both SP1 and ZBP-89 transcriptional func-
tion in HeLa, AGS, and DG75 cells, although its relative effect
on ZBP-89 versus SP1 was cell type dependent. Since the DNA
binding activity in these experiments is mediated through the
GAL4 DNA binding domain, these results suggest that
BMRF1 could potentially activate promoters by enhancing
either SP1 or ZBP-89 transcriptional function. In contrast,
BMRF1 did not activate the transcriptional function of a Jun-
GAL4 fusion protein (data not shown). Interestingly, the
BMRF1 379–383 deletion had a stronger effect on the ability of
BMRF1 to activate ZBP-89–GAL4 than on its ability to acti-
vate SP1-GAL4 (Fig. 8), suggesting that BMRF1 effects on
ZBP-89 are important for its ability to activate the gastrin
promoter.
Lytically induced NPC-KT cells express gastrin. The
BMRF1 protein is expressed during the lytic, but not latent,
form of EBV infection. To determine if gastrin expression can
be induced during the lytic form of EBV infection, NPC-KT
cells were switched from the latent to lytic form of EBV in-
fection by treating the cells with iododeoxyuridine (75 g/ml)
for 48 h as previously described (62). RT-PCR analysis was
performed to quantitate the level of gastrin RNA expression
(Fig. 9). Latently infected NPC-KT cells (which do not express
the BMRF1 protein at a significant level) had no detectable
gastrin expression. As expected, gastrin was expressed at a high
level in AGS cells. Treatment of NPC-KT cells with iodode-
oxyuridine, which induces BMRF1 expression (62), clearly ac-
tivated gastrin gene expression but did not affect the expression
of 2-microglobin. Iododeoxyuridine treatment of EBV-nega-
tive HeLa cells did not activate gastrin expression (data not
shown). However, induction of lytic EBV gene expression by
B-cell receptor engagement in the Akata Burkitt cells did not
result in detectable gastrin gene expression (data not shown).
These results indicate that lytic EBV infection may result in
gastrin gene expression in some, but perhaps not all, EBV-
infected cell types.
DISCUSSION
The EBV BMRF1 gene product, also known as the early
antigen-diffuse protein, not only functions as the viral DNA
polymerase processivity factor but also transcriptionally acti-
vates the oriLyt early viral promoter, BHLF1. However, little is
known regarding the mechanism(s) by which BMRF1 tran-
scriptionally activates promoters. In this report, we demon-
strate that the cellular gastrin promoter is also activated by
BMRF1, and we have investigated the mechanism for this
effect. We show that BMRF1 activation of the gastrin pro-
moter is mediated through two GC-rich motifs in the promoter
that bind to both the SP1 and ZBP-89 cellular transcription
factors. Furthermore, we demonstrate that BMRF1 enhances
the transcriptional function of both ZBP-89–GAL4 and SP1-
GAL4 fusion proteins. Combined with previous findings that
BMRF1 directly interacts with both the ZBP-89 and SP1 pro-
teins (3), our results here suggest that BMRF1 activates pro-
FIG. 5. ZBP-89 binds to both GC-rich motifs in the gastrin pro-
moter. EMSA was performed with in vitro-translated ZBP-89 (or un-
programmed reticulocyte lysate) and radiolabeled oligonucleotide
probes containing the regions of the gastrin promoter indicated or a
strong ZBP-89 binding site in EBV oriLyt.
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moters by enhancing the transcriptional effects of ZBP-89 and
SP1 bound to GC-rich motifs.
The finding that BMRF1 activates gastrin gene transcription
in TIK cells was unexpected, given that gastrin transcription is
normally limited to specialized cells in the stomach (G cells).
The ability of the BMRF1 adenovirus vector to activate gastrin
transcription, which was initially suggested by microarray anal-
ysis, was subsequently confirmed by Northern blot analysis.
Transfection of a BMRF1 expression plasmid into TIK cells
also activated gastrin gene expression, indicating that adeno-
virus-encoded proteins are not required for this effect. BMRF1
also robustly activated the gastrin promoter in reporter gene
assays.
Nevertheless, we have as yet been unable to demonstrate
that BMRF1 induces gastrin protein expression in TIK cells
(data not shown). This negative result may reflect the fact that
the gastrin gene product is extensively posttranslationally mod-
ified in G cells (21, 44, 48) to produce the various different
forms of gastrin. The preprogastrin protein is converted to
multiple different forms of gastrin, including progastrin, gly-
cine-extended gastrin and amidated gastrins. We speculate
that TIK cells are unable to convert the progastrin protein into
the fully processed gastrin (carboxyamidated gastrin-17). In-
terestingly, the alternatively processed forms of gastrin, includ-
ing progastrin and glycine-extended gastrin, are increasingly
recognized as growth factors for gastrointestinal (GI) epithe-
lial cells (44, 45, 49). Whether these alternatively processed
forms of gastrin are induced by BMRF1 expression in nongas-
tric cells types remains an important issue for future research.
The gastrin promoter is only the second promoter (in addi-
tion to the viral BHLF1 promoter) shown to be activated by
BMRF1. The mechanisms by which BMRF1 activates the gas-
trin and BHLF1 promoters are likely to be similar. The
BMRF1-responsive elements in both the BHLF1 and gastrin
promoters contain binding sites for SP1 and ZBP-89. In addi-
tion, residues 379 to 383 in the BMRF1 protein are required
for efficient activation of both promoters.
ZBP-89 (BFCOL1, BERF-1, ZNF 148) is a Kruppel-type
zinc finger transcription factor. Given that only a few promot-
ers have been previously been shown to be regulated by ZBP-
89, it is striking that both of the BMRF1-responsive promoters
contain ZBP-89 binding motifs. The consensus ZBP-89 bind-
ing site, GCCCCTCCXCC, is essentially always also bound by
FIG. 6. BMRF1 enhances binding of ZBP-89 to the gastrin pro-
moter. (a) DG75 cells were transfected with SG5 vector alone, SG5-
BMRF1 expression vector, a Flag-tagged ZBP-89 expression vector, or
the combination of the ZBP-89 vector and SG5-BMRF1. Extracts were
prepared 2 days after transfection and used in EMSAs with a radio-
actively labeled probe containing gastrin promoter sequences from
47 to 74. Antibodies directed against SP1 and SP3 were added in
some conditions to determine the positions of the SP1 and SP3 com-
plexes. Binding of the transfected Flag-tagged ZBP-89 protein was
visualized by using an anti-Flag antibody. (b) Immunoblot analysis of
the transfected DG75 cell extracts used in the EMSA (a) was per-
formed by using the anti-Flag antibody to compare the levels of
ZBP-89 Flag protein in the presence and absence of cotransfected
SG5-BMRF1.
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SP1 and SP3, although the reverse is not true. Interestingly,
ZBP-89 can function as either a negative or positive regulator
of transcription, depending upon the promoter and perhaps
other factors as well (1, 2, 5, 20, 28, 29, 34, 36, 38, 57, 59, 61,
66). Negative regulation of promoters by ZBP-89 (including
the gastrin promoter) in some cases may be due to the ability
of ZBP-89 to compete with SP1 for binding to the same site
(30, 34). However, ZBP-89 and SP1 can simultaneously bind to
the BMRF1-responsive region of the BHLF1 promoter (3).
ZBP-89 also interacts directly with SP1 and may inhibit its
function through this mechanism (57). A basic domain in the
amino terminus of ZBP-89 has been shown to function as a
negative regulator of transcription when fused to the GAL4
DNA binding domain, whereas the carboxy terminus functions
as positive regulator of transcription (37). While SP1 has been
shown to be a positive regulator of both the BHLF1 and gastrin
promoters (6, 16, 64), ZBP-89 by itself is a negative regulator
of the gastrin promoter (29) as well as the BHLF1 promoter
(unpublished data). Thus, in the absence of BMRF1, the rel-
ative amount of SP1 versus ZBP-89 binding to the BHLF1 and
gastrin promoters probably serves to regulate the activity of
these promoters.
EMSAs indicated that BMRF1 expression in cells enhances
the binding of ZBP-89 to the gastrin promoter without signif-
icantly affecting the binding of SP1 or SP3. The ability of
BMRF1 to enhance binding of a negative regulator (ZBP-89)
to the gastrin promoter yet activate gastrin promoter activity
was initially paradoxical. However, the finding that BMRF1
converts the ZBP-89–GAL4 fusion protein into a positive reg-
ulator of transcription explains this paradox. To our knowl-
edge, BMRF1 is the first protein shown to specifically enhance
ZBP-89 transcriptional activity. As yet, the precise mechanism
for this effect remains unknown. BMRF1 itself is not known to
contain a transactivator domain, and a BMRF1-GAL4 fusion
protein does not activate transcription when bound to GAL4
binding sites (4). Given the previously reported direct interac-
tion between BMRF1 and ZBP-89, it is possible that BMRF1
promotes a posttranslational modification of ZBP-89, such as
phosphorylation or acetylation, which enhances both its DNA
binding and transcriptional function. Using EMSAs, we have
been unable to show that BMRF1 is tethered to ZBP-89 bind-
ing sites, although it is possible that the BMRF1/ZBP-89 in-
teraction is disrupted by EMSA conditions.
We also demonstrate in this paper that BMRF1 activates the
transcriptional function of an SP1-GAL4 protein, although in
contrast to its effect on ZBP-89, BMRF1 does not significantly
increase SP1/SP3 binding activity. Our results also indicate that
in some cell types, such as HeLa cells, the effect of BMRF1 on
SP1 transcriptional function is greater than its effect on ZBP
transcriptional function. As is the case for the BMRF1/ZBP-89
interaction, the precise mechanism for the effect of BMRF1 on
SP1 transcriptional function is not yet specifically defined. The
BMRF1 and SP1 proteins have been previously shown to di-
rectly interact, but we have been unable to detect a BMRF1/
SP1 or BMRF1/SP3 complex binding to the gastrin promoter
FIG. 7. BMRF1 enhances the transcriptional function of ZBP-89-
GAL4 and SP1-GAL4 fusion proteins. A construct containing the
CAT gene driven by a minimal E1b promoter and 5 upstream GAL4
binding sites was cotransfected with vectors expressing the GAL4
DNA binding domain alone or fusion proteins containing the GAL4
DNA binding domain linked in-frame to SP1 or ZBP-89 in the pres-
ence or absence of BMRF1. Results are normalized to compare the
fold increase in CAT activity produced by cotransfection with BMRF1
versus the SG5 expression vector for each GAL4 construct.
Experiments were performed with three different cell types: HeLa cells
(a), AGS cells (b), and DG75 cells (c).
752 HOLLEY-GUTHRIE ET AL. J. VIROL.
using EMSAs (unpublished data). It is possible that the
BMRF1/SP1 complex binds to DNA in vivo but cannot survive
the EMSA conditions. Alternatively, BMRF1 may promote a
posttranslational modification of SP1 that enhances its tran-
scriptional function.
In this paper, we have shown that the EBV early protein
BMRF1 activates both the DNA binding activity and the tran-
scriptional function of the ZBP-89 cellular transcription factor.
We have found that, similar to its effects on ZBP-89 binding to
the gastrin promoter, BMRF1 also increases the binding of
ZBP-89 to oriLyt (W. T. Seaman and S. C. Kenney, unpub-
lished data). Given that the ZBP-89 binding site in the EBV
oriLyt is required for oriLyt replication (3), and transfected
ZBP-89 enhances replication of an oriLyt-containing plasmid
(3), our results suggest that the ability of BMRF1 to activate
both ZBP-89 binding activity and its transcriptional activity
may play an important role in promoting EBV lytic replication.
An important issue that remains unanswered is whether the
ability of BMRF1 to activate gastrin gene transcription also
plays a role in viral pathogenesis and/or EBV-associated gas-
tric cancer. It has recently been reported that small EBV-
encoded RNAs expressed during the latent form of EBV in-
fection induce expression of insulin-like growth factor 1 in
gastric cells, and that this EBV-induced release of insulin-like
growth factor 1 may promote gastric tumor formation through
a paracrine mechanism (19). Our results suggest that BMRF1-
mediated activation of gastrin could cooperate with the role of
the EBV-encoded RNAs in promoting gastric cancer through
a paracrine mechanism. The various forms of gastrin are in-
creasingly recognized as important growth factors for GI epi-
thelium (8, 9, 21, 41, 45, 47, 55, 58), and there is growing
evidence linking increased gastrin expression to various GI
malignancies, including gastric cancer and colon cancer (17,
46). Chronic overproduction of gastrin may play a role in
Helicobacter pylori-associated gastric cancer, as well as mucosa-
associated lymphoid tissue lymphomas (25–27, 35, 54). Al-
though we were unable to document that BMRF1 induces
expression of fully processed gastrin (carboxyamidated gastrin-
17) in TIK cells, we speculate that BMRF1 expression in pri-
mary gastric cells capable of properly processing the prepro-
gastrin protein into its various active forms would result in
enhanced release of gastrin and gastrin-related peptides. Thus,
BMRF1 expression in a small number of lytically infected cells
in the stomach could result in potential growth-promoting ef-
fects on neighboring gastric cells and play an early role in the
promotion of gastric cancer. The lytic form of EBV infection
has been documented in some EBV-positive gastric carcino-
mas (18, 32). There is also evidence that the EBV genome may
be present in the gastric epithelium of some patients with
gastritis (60). Whether lytic EBV infection also occurs in nor-
mal stomach tissue and, if so, which of the various gastric cells
types support this type of infection remain important and un-
answered questions.
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FIG. 8. BMRF1 residues 379 to 383 are required for ZBP-89–GAL4 activation. AGS cells were cotransfected with a vector containing the CAT
gene driven by a minimal E1b promoter and five upstream GAL4 binding sites, ZBP-89–GAL4 or SP1-GAL4 constructs and the SG5 expression
vector, the wild-type SG5-BMRF1 construct, or a mutant SG5-BMRF1 construct containing a deletion in BMRF1 residues 379 to 383 were used.
BMRF1-induced activation of CAT activity (relative to that with SG5 alone) is shown.
FIG. 9. Induction of lytic EBV gene expression in NPC-KT cells
results in gastrin expression. Latently infected, EBV-positive NPC-KT
cells were switched to the lytic form of EBV infection by treating the
cells with iododeoxyuridine (IUDR; 75 g/ml) for 48 h as previously
described (62). RT-PCR analysis was performed to quantitate the level
of gastrin RNA expression and 2-microglobin expression. Two differ-
ent dilutions of cDNA were used in the RT-PCRs for 2-microglobin
to ensure that the reaction was in the linear range. No product of the
expected size for gastrin was observed in the absence of RT (data not
shown). AGS cells were used as a positive control for gastrin gene
expression.
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